Combination immune-based therapy for chronic ITP

Update on chronic immune thrombocytopenic purpura (ITP)

Platelet production and circulation Thrombopoietin (TPO), the major cytokine affecting all phases of platelet production, is produced primarily by the liver and binds to the c-Mpl receptor located on platelets, stem cells and megakaryocytes. Upon stimulation, pluripotential stem cells produce cells committed to megakaryocyte differentiation. These cells initially undergo mitosis followed eventu...

Combination therapy for a pregnant woman with severe refractory ITP.

Combination therapy for chronic migraine

Neurology 2012;78:940–941 Chronic migraine (CM) is a frequent and challenging condition for practicing neurologists. It affects around 2% of adults and its prevalence in middleaged women reaches 5%.1 Management of CM is generally unsatisfactory and largely not evidencebased, in part because until recently CM has not been considered a true entity, but mostly a consequence of analgesic overuse. E...

Immune thrombocytopenic purpura (ITP) and breast cancer. Does adjuvant therapy for breast cancer improve platelet counts in ITP?

Although both breast cancer and immune thrombocytopenic purpura (ITP) are common conditions, the simultaneous coexistence of these two diseases is rare. ITP is an autoimmune disease in which the presence of autoantibodies against platelets results in splenic sequestration and thrombocytopenia that may be associated with lymphoid neoplasms [1]. Except for an observational case series of 10patien...

EFFICACY AND SAFETY OF COMBINATION THERAPY OF INTERFERON-ALPHA 2B PLUS RIBAVIRIN FOR CHRONIC HEPATITIS C

Introduction: The aim of this study is to assess the therapeutic efficacy and safety of a particular brand of IFN alpha (PDferon B®) in combination with ribavirin (RlBA) on Iranian patients with chronic hepatitis C (CHC). The addition of RIBA to the standard treatment with interferon (IFN) alpha led to an improvement in sustained virologic response (SVR) from less than 20% with IFN monother...